Chairman Hans Peter Hasler said: “I am delighted that Christian has agreed to join the board of Shield bringing his previous knowledge of the company and Feraccru, and also his extensive experience in medical affairs and clinical development.”
Feraccru, the company’s lead product, is an oral treatment for iron deficiency with or without anaemia, which is approved in the US, Europe, China and elsewhere.
The company highlighted that Schweiger, who was most employed by Shield as a senior medical science advisor between 2016 and 2017, “is an entrepreneurial senior medical affairs and clinical development executive with substantial experience working with both large and small pharmaceutical companies”.
As a lecturing professor in pharmaceutical medicine at the University of Essen in Germany, he actively works with different international patient and professional associations.
He also currently owns 4,114,300 ordinary shares of 1.5p each in Shield, a stake of 3.5%.
Published at Fri, 26 Jun 2020 07:04:00 +0000-Shield Therapeutics brings co-founder Christian Schweiger back onto the board